ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2015

Methotrexate Treatment Is Associated with Reduction of Neutrophil Reactive Oxygen Species and CD177 in RA Patients

Urvashi Kaundal 1, Varun Dhir1, Biman Saikia 1 and Aastha Khullar 1, 1Post Graduate Institute of Medical Education and Research, Chandigarh, India

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: methotrexate (MTX) and neutrophils, Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Session Title: RA – Etiology & Pathogenesis Poster II

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Methotrexate (MTX) is the gold-standard DMARD in rheumatoid arthritis, however, it is unclear how exactly it works. Its effects on neutrophils may involve reduction in ROS production and neutrophil activation markers like CD177, CD11b and CD64.

Methods: This was a single-center cross-sectional study, which recruited patients with rheumatoid arthritis (RA) and healthy controls. RA patients included naïve (could be on low dose steroids) and MTX treated patients (at least 15 mg/week for 6 months), labeled as naïve-RA and MTX-RA groups. Neutrophils were separated from blood using Hetasep and Ficoll density-gradient centrifugation. Reactive oxygen species (ROS) by dihydrorhodamine (DHR) was detected using flow cytometry after PMA stimulation (1.62 ug/ml) as Median Fluorescent Intensity (MFI). ROS by Luminol was detected after adding PMA (0.4 ug/ml) and Luminol (50 uM) and using a luminescence detector (area under curve over 30 mins). Activation markers CD177, CD11b and CD64 were detected by surface staining of neutrophils using FACS.

Results: This study included 53 (F:M= 43:10) patients of rheumatoid arthritis on methotrexate (MTX-RA), 47 (F:M=39:8) naïve (naïve-RA) and 21 healthy controls. There was no significant difference in the mean age (44.5, 47.6 years, p=0.17) between RA groups. There was a significant difference in the DAS28-3 between the naïve-RA and MTX-RA group (6.2, 4.9., p< 0.001). At baseline, there was higher level of ROS by DHR (MFI) in neutrophils of naive-RA compard to MTX-RA (11049, 7301, p=0.009). ROS levels by DHR (MFI) remained higher in naive-RA than MTX-RA (88805, 59637, p=0.0070) even after PMA stimulation.  However there was no significant between MTX-RA and healthy controls after PMA stimulation. No significant difference was found in ROS by luminol between Naive-RA and MTX-RA patients. CD177 was found higher expressed (MFI) in naïve-RA compared to MTX-RA patients (46620, 34475, p=0.0216) and healthy controls (46620, 26855, p= 0.0012). No significant change for CD11b and CD64 levels was observed between naive and MTX treated patients. However, in comparison to healthy controls, MTX-RA patients had lower levels of CD64 (260, 241, p= 0.0115) while both MTX-RA and naïve-RA patients had higher levels of CD11b (3708, 5560, p= 0.0112 and 3708, 5978, p=0.0165).

Conclusion: MTX treatment in RA patients was associated with reduction (reaching healthy control levels) of ROS production in neutrophils. In addition, CD177 expression was also significantly reduced (reaching healthy controls) in MTX- treated patients. One of the ways MTX acts in RA may be through reducing neutrophil activation and ROS.

Top panel shows scatter-plots showing higher reactive-oxygen species detected using dihydrorhodamine in naive-RA than MTX-RA, but no differnce between MTX-RA and healthy controls -both unstimulated and pMA stimulated-. Middle panel shows higher level of CD177 expression in neutrophils of naive-RA than MTX-RA, but no difference in CD64. Lower panel shows higher expression of CD11b in both RA groups than healthy controls.


Disclosure: U. Kaundal, None; V. Dhir, None; B. Saikia, None; A. Khullar, None.

To cite this abstract in AMA style:

Kaundal U, Dhir V, Saikia B, Khullar A. Methotrexate Treatment Is Associated with Reduction of Neutrophil Reactive Oxygen Species and CD177 in RA Patients [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/methotrexate-treatment-is-associated-with-reduction-of-neutrophil-reactive-oxygen-species-and-cd177-in-ra-patients/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/methotrexate-treatment-is-associated-with-reduction-of-neutrophil-reactive-oxygen-species-and-cd177-in-ra-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences